Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023
April 27 2023 - 4:05PM
Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic
and synthetic biology solutions, today announced that it will
release its first quarter 2023 financial results on Thursday, May
11, 2023, after the market closes. In conjunction with the release,
management will host a conference call on Thursday, May 11, 2023,
at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the
financial results and recent corporate highlights.
The press release and live audio webcast can be
accessed via the Investor section of Telesis Bio’s website at
https://ir.telesisbio.com/. The conference call can be accessed by
registering at this link:
https://register.vevent.com/register/BIf9b7641fab2948fca7b1ec1d400ceec4.
Please log in approximately 5 to 10 minutes before the event to
ensure a timely connection. Upon registration, all telephone
participants will receive the dial-in number along with a unique
PIN number that can be used to access the call. A replay of the
conference call webcast will be available shortly after the live
event and archived on the Investors section of the
Telesis Bio website for at least 30 days.
About Telesis BioTelesis Bio is
empowering scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® system consolidates, automates,
and optimizes the entire synthesis, cloning and amplification
workflow. As a result, it delivers virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly,
and BioXp are trademarks of Telesis Bio Inc.
Contact:Jen CarrollVice President of Investor
Relationsjen.carroll@telesisbio.com
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From May 2023 to May 2024